Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study
- PMID: 28433332
- DOI: 10.1016/j.jvs.2017.01.067
Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from a Swedish nationwide study
Abstract
Objective: Long-term progression of peripheral arterial disease (PAD) as initial manifestation of atherosclerotic arterial disease is not well described. Cardiovascular (CV) risk was examined in different PAD populations diagnosed in a hospital setting in Sweden.
Methods: Data for this retrospective cohort study were retrieved by linking data on morbidity, medication use, and mortality from Swedish national registries. Primary CV outcome was a composite of myocardial infarction, ischemic stroke (IS), and CV death. Kaplan-Meier analysis and Cox proportional hazards modeling was used for describing risk and relative risk.
Results: Of 66,189 patients with an incident PAD diagnosis (2006-2013), 40,136 had primary PAD, 16,786 had PAD + coronary heart disease (CHD), 5803 had PAD + IS, and 3464 had PAD + IS + CHD. One-year cumulative incidence rates of major CV events for the groups were 12%, 21%, 29%, and 34%, respectively. Corresponding numbers for 1-year all-cause death were 16%, 22%, 33%, and 35%. Compared with the primary PAD population, the relative risk increase for CV events was highest in patients with PAD + IS + CHD (hazard ratio [HR], 2.01), followed by PAD + IS (HR, 1.87) and PAD + CHD (HR, 1.42). Despite being younger, the primary PAD population was less intensively treated with secondary preventive drug therapy.
Conclusions: PAD as initial manifestation of atherosclerotic disease diagnosed in a hospital-based setting conferred a high risk: one in eight patients experienced a major CV event and one in six patients died within 1 year. Despite younger age and substantial risk of future major CV events, patients with primary PAD received less intensive secondary preventive drug therapy.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study.Eur J Prev Cardiol. 2015 Mar;22(3):317-25. doi: 10.1177/2047487313519344. Epub 2014 Jan 7. Eur J Prev Cardiol. 2015. PMID: 24398369
-
Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization.J Vasc Surg. 2016 Oct;64(4):1009-1017.e3. doi: 10.1016/j.jvs.2016.03.429. Epub 2016 May 18. J Vasc Surg. 2016. PMID: 27209402
-
Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction.Circ Cardiovasc Qual Outcomes. 2012 Jul 1;5(4):541-9. doi: 10.1161/CIRCOUTCOMES.111.964379. Epub 2012 Jun 19. Circ Cardiovasc Qual Outcomes. 2012. PMID: 22715460 Free PMC article.
-
The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness.Dan Med J. 2012 Sep;59(9):B4514. Dan Med J. 2012. PMID: 22951205 Review.
-
Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis.Thromb Haemost. 2020 May;120(5):866-875. doi: 10.1055/s-0040-1709711. Epub 2020 May 5. Thromb Haemost. 2020. PMID: 32369857
Cited by
-
Antiplatelet therapy for peripheral artery disease.Cardiovasc Diagn Ther. 2018 Oct;8(5):663-677. doi: 10.21037/cdt.2018.07.02. Cardiovasc Diagn Ther. 2018. PMID: 30498689 Free PMC article. Review.
-
Peripheral Arterial Disease and Its Associated Factors among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia.J Diabetes Res. 2020 Jan 29;2020:9419413. doi: 10.1155/2020/9419413. eCollection 2020. J Diabetes Res. 2020. PMID: 32090126 Free PMC article.
-
Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials.Clin Cardiol. 2018 Jan;41(1):137-143. doi: 10.1002/clc.22839. Epub 2018 Jan 22. Clin Cardiol. 2018. PMID: 29355992 Free PMC article. Review.
-
A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention.Sci Rep. 2023 Feb 13;13(1):2502. doi: 10.1038/s41598-023-29006-z. Sci Rep. 2023. PMID: 36781928 Free PMC article. Clinical Trial.
-
Frequency of Care and Mortality Following an Incident Diagnosis of Peripheral Artery Disease in the Inpatient or Outpatient Setting: The ARIC (Atherosclerosis Risk in Communities) Study.J Am Heart Assoc. 2018 Apr 13;7(8):e007332. doi: 10.1161/JAHA.117.007332. J Am Heart Assoc. 2018. PMID: 29654201 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical